Our results implicate FMO5 as a regulator of body weight and of glucose disposal and insulin sensitivity and, thus, identify FMO5 as a potential novel therapeutic target for obesity and insulin resistance. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.